“PD-1 and PD-L1 Inhibitors Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 and PD-L1 Inhibitors Market.
The PD-1 and PD-L1 Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the PD-1 and PD-L1 Inhibitors Pipeline Report:
Companies across the globe are diligently working toward developing novel PD-1 and PD-L1 Inhibitors treatment therapies with a considerable amount of success over the years.
PD-1 and PD-L1 Inhibitors companies working in the treatment market are Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others, are developing therapies for the PD-1 and PD-L1 Inhibitors treatment
Emerging PD-1 and PD-L1 Inhibitors therapies such as – CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others are expected to have a significant impact on the PD-1 and PD-L1 Inhibitors market in the coming years.
In May 2025, Clinical-stage biopharma company OmRx Oncology (OmRx) has launched a randomized Phase II trial for its oral PD-L1 inhibitor, OX-4224, aimed at patients with non-small cell lung cancer (NSCLC). The company believes this investigational small molecule could provide a more affordable and accessible alternative to current antibody-based treatments. The open-label study plans to enroll around 50 metastatic NSCLC patients, primarily in India, who have not previously received immune checkpoint inhibitor therapies. OX-4224 will be assessed as a second-line monotherapy in this patient population.
In March 2025, Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, has announced a new clinical program featuring trials of Actimab-A combined with either KEYTRUDA® (pembrolizumab) or OPDIVO® (nivolumab). These blockbuster PD-1 inhibitors, developed by Merck & Co. and Bristol Myers Squibb respectively, together generated $38.8 billion in sales in 2024 across multiple solid tumor indications. Despite their success, their effectiveness is often limited by Myeloid Derived Suppressor Cells (MDSCs), which accumulate in the tumor microenvironment and express the CD33 antigen — the specific target of Actimab-A. The trials aim to explore whether depleting MDSCs with Actimab-A can enhance the efficacy of these immunotherapies.
In January 2025, ImmunityBio, Inc. (NASDAQ: IBRX) announced a new collaboration and supply agreement with BeiGene, Ltd. (soon to be renamed BeOne Medicines, Ltd.), a global oncology company, to conduct a pivotal randomized Phase 3 trial (ResQ201A-NSCLC). This trial will combine BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-pmln). The ResQ201A-NSCLC study (NCT06745908) aims to validate the efficacy and safety of this combination, previously shown in the QUILT 3.055 trial, and provide evidence that these two immunotherapies can enhance overall survival in patients with advanced or metastatic NSCLC who have developed resistance to immune CPI treatments.
PD-1 and PD-L1 Inhibitors Overview
PD-1 (programmed cell death protein 1) is found on the surface of cancer cells. It is used by tumors to evade the immune system so blocking its action enables the body to attack and kill cancer. T cells constantly monitor our body for abnormal cells and eliminate them before they can turn into cancer
Get a Free Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
Emerging PD-1 and PD-L1 Inhibitors Drugs Under Different Phases of Clinical Development Include:
CTX-8371: Compass Therapeutics
CA 327: Aurigene Discovery Technologies
RC-98: RemeGen
AUR-106: Aurigene Discovery Technologies
INBRX 105: Inhibrx
Tomivosertib: Effector Therapeutics
CX-072: CytomX Therapeutics
IBI 323: Innovent Biologics
Jemperli: GlaxoSmithKline
BCD-100: Biocad
TECENTRIQ: Genentech
Opdivo: Bristol Myers Squibb
KEYTRUDA: Merck
PD-1 and PD-L1 Inhibitors Pipeline Therapeutics Assessment
PD-1 and PD-L1 Inhibitors Assessment by Product Type
PD-1 and PD-L1 Inhibitors By Stage and Product Type
PD-1 and PD-L1 Inhibitors Assessment by Route of Administration
PD-1 and PD-L1 Inhibitors By Stage and Route of Administration
PD-1 and PD-L1 Inhibitors Assessment by Molecule Type
PD-1 and PD-L1 Inhibitors by Stage and Molecule Type
DelveInsight’s PD-1 and PD-L1 Inhibitors Report covers around 200+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further PD-1 and PD-L1 Inhibitors product details are provided in the report. Download the PD-1 and PD-L1 Inhibitors pipeline report to learn more about the emerging PD-1 and PD-L1 Inhibitors therapies
Some of the key companies in the PD-1 and PD-L1 Inhibitors Therapeutics Market include:
Key companies developing therapies for PD-1 and PD-L1 Inhibitors are – F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, Others.
PD-1 and PD-L1 Inhibitors Pipeline Analysis:
The PD-1 and PD-L1 Inhibitors pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 and PD-L1 Inhibitors with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 and PD-L1 Inhibitors Treatment.
PD-1 and PD-L1 Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
PD-1 and PD-L1 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 and PD-L1 Inhibitors market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about PD-1 and PD-L1 Inhibitors drugs and therapies
PD-1 and PD-L1 Inhibitors Pipeline Market Drivers
Rise in prevalence of Cancer, PD-1 and PD-L1 Inhibitors are emerging as an important checkpoint inhibitors used as frontline treatment in various cancer are some of the important factors that are fueling the PD-1 and PD-L1 Inhibitors Market.
PD-1 and PD-L1 Inhibitors Pipeline Market Barriers
However, high cost associated with the treatment, side effects associated with the treatment and other factors are creating obstacles in the PD-1 and PD-L1 Inhibitors Market growth.
Scope of PD-1 and PD-L1 Inhibitors Pipeline Drug Insight
Coverage: Global
Key PD-1 and PD-L1 Inhibitors Companies: Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Aurigene Discovery Technologies, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, Merck, and others
Key PD-1 and PD-L1 Inhibitors Therapies: CTX-8371, CA 327, RC-98, AUR-106, INBRX 105, Tomivosertib, CX-072, IBI 323, Jemperli, BCD-100, TECENTRIQ, Opdivo, KEYTRUDA, and others
PD-1 and PD-L1 Inhibitors Therapeutic Assessment: PD-1 and PD-L1 Inhibitors current marketed and PD-1 and PD-L1 Inhibitors emerging therapies
PD-1 and PD-L1 Inhibitors Market Dynamics: PD-1 and PD-L1 Inhibitors market drivers and PD-1 and PD-L1 Inhibitors market barriers
Request for Sample PDF Report for PD-1 and PD-L1 Inhibitors Competitive Assessment and clinical trials
Table of Contents
1
PD-1 and PD-L1 Inhibitors Report Introduction
2
PD-1 and PD-L1 Inhibitors Executive Summary
3
4
PD-1 and PD-L1 Inhibitors- Analytical Perspective In-depth Commercial Assessment
5
PD-1 and PD-L1 Inhibitors Pipeline Therapeutics
6
PD-1 and PD-L1 Inhibitors Late Stage Products (Phase II/III)
7
PD-1 and PD-L1 Inhibitors Mid Stage Products (Phase II)
8
PD-1 and PD-L1 Inhibitors Early Stage Products (Phase I)
9
PD-1 and PD-L1 Inhibitors Preclinical Stage Products
10
PD-1 and PD-L1 Inhibitors Therapeutics Assessment
11
PD-1 and PD-L1 Inhibitors Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
PD-1 and PD-L1 Inhibitors Key Companies
14
PD-1 and PD-L1 Inhibitors Key Products
15
PD-1 and PD-L1 Inhibitors Unmet Needs
16
PD-1 and PD-L1 Inhibitors Market Drivers and Barriers
17
PD-1 and PD-L1 Inhibitors Future Perspectives and Conclusion
18
PD-1 and PD-L1 Inhibitors Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
